Logomix

The core of Logomix's business is its proprietary Geno-Writing™ platform, a technology that enables the precise engineering and modification of megabase (Mb)-scale genomic sequences within human cells. This platform allows for rapid, extensive, and complex genetic alterations, positioning it as a foundational technology for creating 'super-functionalized' cells. The company's business model centers on providing this platform as a service and engaging in collaborative partnerships with biotech and pharmaceutical companies to accelerate the development of next-generation therapies. Its primary markets are cell therapy, regenerative medicine, and drug discovery.

Logomix serves clients in the biopharma industry by offering its Geno-Writing™ platform for discovery collaborations and by providing engineered human cell models for diseases linked to large chromosomal modifications. For instance, the company has developed universal donor iPS (induced pluripotent stem) cell lines available for licensing. It collaborates with partners like HebeCell to develop gene-edited NK cells for cancer treatment and Somite Therapeutics to integrate machine learning for enhanced therapeutic outcomes. Since a seed round of $3.9 million (¥500 million) in early 2023, Logomix secured an additional $19 million in a subsequent funding round in mid-2025 to fuel its US expansion and commercialization efforts. Key investors include Angel Bridge, JAFCO, UTokyo IPC, Globis Capital Partners, and Sand Hill Angels.